Albert David Ltd (IN:ALBERTDAVD)
:ALBERTDAVD
Want to see IN:ALBERTDAVD full AI Analyst Report?
Top Page
Albert David Ltd
(ALBERTDAVD)
Select Model
Select Model
Rating:55Neutral
Price Target:
₹742.00
▼(-5.89% Downside)
Action:Reiterated
Date:05/17/26
The score is held back primarily by weakened operating results and cash flow (loss in 2026 and negative operating/free cash flow in 2025–2026), despite a conservatively financed balance sheet. Technical signals are mixed/neutral, while the low P/E supports the score on valuation.
Positive Factors
Balance sheet strength
Albert David's conservative financing — low leverage and substantially grown equity and assets — provides durable financial resilience. This structural strength supports credit flexibility, withstands short-term cash stress, and preserves capacity for capex or working-capital needs over the next several months.
Negative Factors
Weak cash generation
The shift from positive operating and free cash flow (2021–2024) to sustained negative cash flows in 2025–2026 is a durable operational concern. Persistent cash deficits can force external financing, constrain investment, and increase liquidity risk if working-capital dynamics aren't restored.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Albert David's conservative financing — low leverage and substantially grown equity and assets — provides durable financial resilience. This structural strength supports credit flexibility, withstands short-term cash stress, and preserves capacity for capex or working-capital needs over the next several months.
Read all positive factors
Albert David Ltd (ALBERTDAVD) vs. iShares MSCI India ETF (INDA)
Market Cap
₹4.01B
Dividend Yield0.66%
Average Volume (3M)210.00
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth-3.52%
EPS Growth-108.70%
CountryIN
Employees1,497
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-26.43
Shares Outstanding5,707,162
10 Day Avg. Volume184
30 Day Avg. Volume210
Financial Highlights & Ratios
PEG Ratio2.06
Price to Book (P/B)0.86
Price to Sales (P/S)1.00
P/FCF Ratio-9.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Albert David Ltd Business Overview & Revenue Model
Company Description
Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, bulk drugs, and disposable syringes and needles in India. It offers formulations for parenterals, oral/enteral, topical agents, a...
How the Company Makes Money
Albert David Ltd makes money primarily by selling pharmaceutical products (mainly finished dosage formulations) to customers such as wholesalers, distributors, hospitals, pharmacies, and other institutional buyers. Revenue is generated from the in...
Albert David Ltd Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
78
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.16B | 3.34B | 3.46B | 3.60B | 3.42B | 3.12B |
| Gross Profit | 1.75B | 1.07B | 2.29B | 2.32B | 2.18B | 1.95B |
| EBITDA | -359.98M | 54.67M | 30.26M | 1.05B | 598.68M | 567.76M |
| Net Income | -150.80M | -14.95M | 172.01M | 754.20M | 361.75M | 352.58M |
Balance Sheet | ||||||
| Total Assets | 5.33B | 5.19B | 5.11B | 4.98B | 4.23B | 4.03B |
| Cash, Cash Equivalents and Short-Term Investments | 2.84B | 2.58B | 2.44B | 2.85B | 2.03B | 1.75B |
| Total Debt | 414.14M | 297.11M | 123.17M | 33.24M | 53.18M | 56.62M |
| Total Liabilities | 1.39B | 1.28B | 1.19B | 1.15B | 1.12B | 1.23B |
| Stockholders Equity | 3.94B | 3.92B | 3.92B | 3.83B | 3.12B | 2.79B |
Cash Flow | ||||||
| Free Cash Flow | -271.21M | -350.95M | -432.92M | 346.28M | 52.78M | 292.83M |
| Operating Cash Flow | -208.45M | -59.83M | -284.36M | 455.02M | 105.15M | 403.65M |
| Investing Cash Flow | -46.97M | -85.53M | 233.01M | -332.48M | -49.95M | -396.97M |
| Financing Cash Flow | 248.82M | 144.00M | 1.10M | -82.70M | -63.62M | -12.59M |
Albert David Ltd Technical Analysis
Negative
788.40
Price Trends
700.59
Positive
709.50
Negative
759.02
Negative
Market Momentum
3.98
Positive
45.11
Neutral
9.78
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALBERTDAVD, the sentiment is Negative. The current price of 788.4 is above the 20-day moving average (MA) of 738.42, above the 50-day MA of 700.59, and above the 200-day MA of 759.02, indicating a neutral trend. The MACD of 3.98 indicates Positive momentum. The RSI at 45.11 is Neutral, neither overbought nor oversold. The STOCH value of 9.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALBERTDAVD.
Albert David Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ₹5.35B | 19.82 | ― | ― | -1.22% | -52.32% | |
59 Neutral | ₹2.11B | -338,564.26 | ― | ― | 0.76% | -116.54% | |
55 Neutral | ₹4.01B | -224.07 | ― | 0.66% | -3.52% | -108.70% | |
52 Neutral | ₹2.74B | 7.63 | ― | ― | -57.41% | -2188.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ₹2.66B | -2.82 | ― | ― | -2.19% | -1573.69% | |
49 Neutral | ₹1.45B | 10.71 | ― | ― | 15.44% | ― |
* Healthcare Sector Average
IN:ALBERTDAVD
Albert David Ltd
706.50
-101.72
-12.59%
IN:BROOKS
Brooks Laboratories Limited
51.53
-84.72
-62.18%
IN:LYKALABS
Lyka Labs Limited
61.42
-57.18
-48.21%
IN:NECLIFE
Nectar Lifesciences Ltd.
12.39
-11.45
-48.03%
IN:VIKASLIFE
Vikas Lifecare Limited
1.44
-1.24
-46.27%
IN:ZIMLAB
Zim Laboratories Ltd.
100.00
8.69
9.52%
Albert David Ltd Corporate Events
Albert David Publishes Notice on Re-Lodgement of 300 Physical Shares
Mar 13, 2026
Albert David Ltd has disclosed that it received a request from investor Bharat Kumar N Jain for transfer of 300 physical equity shares into his name, relating to securities previously purchased but not transferred. In line with SEBI guidelines on ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.